INS and type 1 diabetes mellitus: We propose that, to achieve a significant clinical impact in T1D, we need antigen-specific immunotherapies (ASI) that work in the pre-dysglycemic stage into the early insulin-requiring period of disease, preventing and reverting overt disease manifestations.